Evidence map›Paper›PMID 42301817›Full record

ArticleSTAR protocols2026

Protocol for expressing and purifying recombinant full-length Tau by combining affinity chromatography with preparative HPLC.

Ruiheng Jing, Sayanta Mahapatra, Abhishek Bimali, Morgane Herlory, Maciej A Walczak

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in STAR protocols, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ruiheng JingUniversity of Colorado, Department of Chemistry, Boulder, CO 80309, USA. Electronic address: ruiheng.jing@colorado.edu.
Sayanta MahapatraUniversity of Colorado, Department of Chemistry, Boulder, CO 80309, USA. Electronic address: sayanta.mahapatra@colorado.edu.
Abhishek BimaliUniversity of Colorado, Department of Chemistry, Boulder, CO 80309, USA.
Morgane HerloryUniversity of Colorado, Department of Chemistry, Boulder, CO 80309, USA.
Maciej A WalczakUniversity of Colorado, Department of Chemistry, Boulder, CO 80309, USA. Electronic address: maciej.walczak@colorado.edu.

Funding

Non-enzymatic post-translational modifications as drivers of AD pathologyR01AG087295 · NIA · UNIVERSITY OF COLORADO · PI Maciej Walczak · 2024 to 2026
$2.2M
Dissecting the role of tau glycosylation in Alzheimer's diseaseR01AG079294 · NIA · UNIVERSITY OF COLORADO · PI Maciej Walczak · 2026 to 2026
$681k
NIA NIH HHS R01 AG079294NIA NIH HHS R01 AG087295
6 · The paper itself

Abstract

Deposits of microtubule-associated protein full-length Tau (Tau2N4R) are implicated as a hallmark of Alzheimer's disease. Its biochemical and structural characterization is key to understanding disease progression, aggregate toxicity, and designing therapeutics. We present a protocol for expressing and purifying Tau2N4R by combining affinity chromatography with preparative high-performance liquid chromatography (HPLC). We describe steps for linking an N-terminal hexahistidine tag and a cleavable SUMO tag to Tau2N4R. This purification ensures an ultrapure Tau2N4R that gives rise to heparin-induced and cofactor-free in vitro fibrillation.

Indexed as

BiophysicsMass SpectrometryProtein expression and purification

Identifiers

PMID42301817
PMCPMC13292553

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.